Roche: study in lung cancer failed and halted
(CercleFinance.com) - Roche announces the failure of its phase II/III study SKYSCRAPER-06, evaluating tiragolumab in combination with Tecentriq and chemotherapy as first-line treatment for metastatic non-squamous non-small cell lung cancer.
While safety was consistent with previous studies, SKYSCRAPER-06 did not meet the primary endpoints of progression-free survival in the primary analysis and overall survival in the first interim analysis.
The combination showed reduced efficacy compared with the comparator group, leading the Swiss healthcare group to discontinue the trial. It will evaluate any relevant changes required to the ongoing tiragolumab program.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
While safety was consistent with previous studies, SKYSCRAPER-06 did not meet the primary endpoints of progression-free survival in the primary analysis and overall survival in the first interim analysis.
The combination showed reduced efficacy compared with the comparator group, leading the Swiss healthcare group to discontinue the trial. It will evaluate any relevant changes required to the ongoing tiragolumab program.
Copyright (c) 2024 CercleFinance.com. All rights reserved.